Search
Structure Therapeutics Inc
GPCRAdd to Watchlist
48.040USD
-1.430-2.89%
Close 07-31 16:00（ET）Quotes delayed by 15 min
3.41BMarket Cap
LossP/E TTM
More Details of Structure Therapeutics Inc Company
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
Structure Therapeutics Inc Info
Ticker SymbolGPCR
Company nameStructure Therapeutics Inc
IPO dateFeb 03, 2023
CEOStevens (Raymond)
Number of employees163
Security typeDepository Receipt
Fiscal year-endFeb 03
Address601 Gateway Blvd Suite 900
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone16504571978
Websitehttps://structuretx.com/
Ticker SymbolGPCR
IPO dateFeb 03, 2023
CEOStevens (Raymond)
Company Executives of Structure Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
41.17K
--
Dr. Xichen Lin, Ph.D.
Dr. Xichen Lin, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
17.86K
--
Ms. Yingli Ma
Ms. Yingli Ma
Chief Technology Officer
Chief Technology Officer
9.64K
-403.45%
Dr. Raymond Stevens, Ph.D.
Dr. Raymond Stevens, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
--
--
Mr. Jun Yoon
Mr. Jun Yoon
Chief Financial Officer, Co-Founder
Chief Financial Officer, Co-Founder
--
--
Ms. Sharon Tetlow
Ms. Sharon Tetlow
Independent Director
Independent Director
--
--
Mr. Eric L. Dobmeier, J.D.
Mr. Eric L. Dobmeier, J.D.
Independent Director
Independent Director
--
--
Dr. Joanne Waldstreicher, M.D.
Dr. Joanne Waldstreicher, M.D.
Independent Director
Independent Director
--
--
Dr. Ted W. Love, M.D.
Dr. Ted W. Love, M.D.
Independent Director
Independent Director
--
--
Mr. Angus C. Russell
Mr. Angus C. Russell
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
41.17K
--
Dr. Xichen Lin, Ph.D.
Dr. Xichen Lin, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
17.86K
--
Ms. Yingli Ma
Ms. Yingli Ma
Chief Technology Officer
Chief Technology Officer
9.64K
-403.45%
Dr. Raymond Stevens, Ph.D.
Dr. Raymond Stevens, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
--
--
Mr. Jun Yoon
Mr. Jun Yoon
Chief Financial Officer, Co-Founder
Chief Financial Officer, Co-Founder
--
--
Ms. Sharon Tetlow
Ms. Sharon Tetlow
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Structure Therapeutics Inc?
The top five shareholders of Structure Therapeutics Inc are: Mr. Daniel G. Welch
How many institutions hold shares of Structure Therapeutics Inc (GPCR)?
As of 2026Q1, 447 institutions hold shares of Structure Therapeutics Inc, with a combined market value of approximately 67.74M, accounting for 95.31% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -5354411.00.